Biologic characteristics of premalignant breast disease

Issue title: Translational Pathology of Early Cancer

Guest editors: Sudhir Srivastavax and William E. Grizzley

Article type: Research Article

Authors: Cole, Kimberly^a | Tabernero, Maria^b | Anderson, Karen S.^{c; *}

Affiliations: [a] Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, USA | [b] Hospital Universitario de Salamanca, Laboratorio Unidad de Investigacion, Salamanca, Spain | [c] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA | [x] Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA | [y] Department of Pathology, Division of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, USA

Correspondence: [*] Corresponding author: Karen S, Anderson, M.D., Ph.D., HIM 416, 77 Ave Louis Pasteur, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, 02115, USA. Tel.: +1 617 632 5931; Fax: +1 617 632 3966; E-mail: kanderson@partners.org.

Abstract: Breast cancer is the second leading cause of cancer death in women in the United States. While mammography and breast magnetic resonance imaging (MRI) improve detection of early disease, there remains an unmet need for biomarkers for risk stratification, early detection, prediction, and disease prognosis. A number of early breast lesions, from atypical hyperplasias to carcinomas in situ, are associated with an increased risk of developing subsequent invasive breast carcinoma. The recent development of genomic, epigenomic, and proteomic tools for tissue biomarker detection, including array CGH, RNA expression microarrays, and proteomic arrays have identified a number of potential biomarkers that both identify patients at increased risk, as well as provided insights into the pathology of early breast cancer development. This chapter focuses on the detection and application of tissue and serum biomarkers for the identification and risk stratification of early breast cancer lesions.

Keywords: Breast cancer, benign breast disease, biomarkers

DOI: 10.3233/CBM-2011-0187

Journal: Cancer Biomarkers, vol. 9, no. 1-6, pp. 177-192, 2011